Search
News
Novel Immunotherapy Approach at Roswell Park Shows Promise in Metastatic Triple-Negative Breast Cancer
… led the study under the scientific leadership of Pawel Kalinski, MD, PhD, senior author of the paper, Chair of … Cancer Institute and U.S. Department of Defense, Dr. Kalinski directed earlier preclinical studies demonstrating … an easy-to-apply, short-term systemic treatment,” says Dr. Kalinski. CKM also may hold promise for treating other types …
News
Researchers Seek to Expand Immunotherapy Options for Patients with Advanced Breast and Colorectal Cancer
… development at Roswell Park under the leadership of Pawel Kalinski, MD, PhD, involving modulation of key proteins known … to immunotherapy and other forms of cancer treatment. Dr. Kalinski, Chair of the Department of Immunology and Chief of … development at Roswell Park under the leadership of Pawel Kalinski, MD, PhD, involving modulation of key proteins known …
Pancreatic Cancer Research Center
… X, Chakraborty S, Fountzilas C, Wang J, Jamroze A, Liu X, Kalinski P, Tang DG. Role of the DEAD-box RNA helicase DDX5 … PMCID: PMC9925045. 2022 Zhu Z, McGray AJR, Jiang W, Lu B, Kalinski P, Guo ZS. Improving cancer immunotherapy by … SG, Sexton S, Sait SJ, Singh PK, Wang J, Maitra A, Kalinski P, DePinho RA, Wang H, Liao W, Abrams SI, Segal BH, …
Blog Post
Cancer Innovations: Making immunotherapy work for more patients
… of the most commonly prescribed immunotherapies,” says Dr. Kalinski. Other clinical trials at Roswell Park involve … of the most commonly prescribed immunotherapies,” says Dr. Kalinski. Other clinical trials at Roswell Park involve …
News
Roswell Park Clinical Trial Points Toward Promising New Therapy for Most Aggressive Type of Breast Cancer
… increases the risk of immune-related adverse events. Pawel Kalinski, MD, PhD , Professor of Immunology at Roswell Park, … increases the risk of immune-related adverse events. Pawel Kalinski, MD, PhD , Professor of Immunology at Roswell Park, …
Advanced Tissue Imaging Shared Resource (ATISR)
… Minderman H, Maguire O, O'Connor TL, Early AP, Levine EG, Kalinski P. Systemic infusion of TLR3-ligand and IFN-α in … SI, Wang C, Hutson AD, Attwood K, Hicks KA, Jurcevic JA, Kalinski P, Iyer R, Boland PM. Phase Ib/II Study of Cetuximab …
Department of Molecular & Cellular Biology
… K, Stablewski AB, Yan L, Ciesielski MJ, Zhang J, Evans SS, Kalinski P, Hait NC. BRSK2 plays a role in autophagy and …
Tumor Immunology & Immunotherapy Research Program
… Minderman H, Maguire O, O'Connor TL, Early AP, Levine EG, Kalinski P. Systemic infusion of TLR3-ligand and IFN-α in … SG, Sexton S, Sait SJ, Singh PK, Wang J, Maitra A, Kalinski P, DePinho RA, Wang H, Liao W, Abrams SI, Segal BH, … A, Elishaev E, Kang C, Tseng G, Gooding W, Edwards RP, Kalinski P, Vlad AM. Phase I Trial Combining …
Comparative Oncology Shared Resource (COSR)
… SG, Sexton S, Sait SJ, Singh PK, Wang J, Maitra A, Kalinski P, DePinho RA, Wang H, Liao W, Abrams SI, Segal BH, …